Global ACE Inhibitors Market to Reach USD 44.95 Billion by 2031 | CAGR of 5.3%
Category : Healthcare | Published Date : Oct 2024 | Type : Press Release
ACE Inhibitors Market Scope & Overview:
As per the Consegic Business Intelligence newly published report, the ACE Inhibitors Market was valued at USD 6.70 Billion in 2023 and is projected to reach USD 9.78 Billion by 2031, growing at a CAGR of 4.8% during the forecast period from 2024 to 2031. ACE inhibitors, or angiotensin-converting enzyme inhibitors, are medications used primarily for managing high blood pressure, heart failure, and kidney diseases. These inhibitors function by blocking the enzyme that produces angiotensin II, which narrows blood vessels. By reducing angiotensin II production, ACE inhibitors help to relax blood vessels, lower blood pressure, and enhance heart efficiency.
The report comprises the ACE Inhibitors Market Share, Size & Industry Analysis, By Drug Type (Captopril, Enalapril, Lisinopril, Ramipril, Fosinopril, Quinapril, Benazepril, Others), By Application (Hypertension, Congestive Heart Failure, Chronic Kidney Disorders, Cardiovascular Diseases, Others), By Route of Administration (Oral, Intravenous), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Forecast, 2024-2031.
The report contains detailed information on ACE Inhibitors Market Trends, Opportunities, Value, Growth Rate, Segmentation, Geographical Coverage, Company Profile, In-depth Expert Analysis, Revenue Forecast, Competitive Landscape, Growth Factors, Restraints or Challenges, Environment & Regulatory Landscape, PESTLE Analysis, PORTER Analysis, Key Technology Landscape, Value Chain Analysis, and Cost Analysis.
The rising prevalence of hypertension and cardiovascular diseases is a primary market driver, as ACE inhibitors are widely prescribed to manage these conditions. Additionally, emerging markets and combination therapies are creating new opportunities for growth.
Segmental Analysis :
Based on drug type, the market is segmented into captopril, enalapril, lisinopril, ramipril, fosinopril, quinapril, benazepril, and others.
- Lisinopril accounted for the largest market share in 2023 due to its high efficacy and favorable safety profile, making it a preferred choice for managing hypertension and heart failure.
- Ramipril is anticipated to grow at the fastest rate, driven by its cardioprotective benefits, particularly for high-risk cardiovascular patients.
Based on application, the market is segmented into hypertension, congestive heart failure, chronic kidney disorders, cardiovascular diseases, and others.
- Hypertension held the largest market share in 2023, as ACE inhibitors are a first-line treatment for managing high blood pressure. The segment benefits from the increasing global prevalence of hypertension.
- Chronic kidney disorders are expected to witness rapid growth, driven by the increasing incidence of diabetes and hypertension, which contribute to kidney issues.
Based on route of administration, the market is segmented into oral and intravenous.
- Oral administration led the market in 2023, owing to its convenience, cost-effectiveness, and ease of compliance for chronic conditions.
- Intravenous administration is projected to grow rapidly, mainly used in acute settings such as hospitals where immediate therapeutic effects are needed.
Based on distribution channel, the market is divided into hospital pharmacies, retail pharmacies, and online pharmacies.
- Hospital pharmacies accounted for the largest share in 2023, as hospitals are primary providers for ACE inhibitors, especially for patients requiring specialized care.
- Online pharmacies are expected to witness the fastest growth, supported by increasing patient preference for convenient, cost-effective options for long-term prescriptions.
Based on regions, the global market is segmented into North America, Europe, Asia Pacific, Middle East & Africa, and Latin America.
- North America held the largest market share in 2023, driven by a high prevalence of cardiovascular conditions and an advanced healthcare infrastructure.
- Asia Pacific is projected to experience the fastest growth, with rising hypertension cases due to urbanization, lifestyle changes, and healthcare investments.
| Report Attributes | Report Details |
| Study Timeline | 2018-2031 |
| Market Size in 2031 | USD 9.78 Billion |
| CAGR (2024-2031) | 4.8% |
| By Drug Type | Captopril, Enalapril, Lisinopril, Ramipril, Fosinopril, Quinapril, Benazepril, Others |
| By Application | Hypertension, Congestive Heart Failure, Chronic Kidney Disorders, Cardiovascular Diseases, Others |
| By Route of Administration | Oral, Intravenous |
| By Distribution Channel | Hospital Pharmacies, Retail Pharmacies, Online Pharmacies |
| By Region | North America(U.S., Canada, Mexico) Europe(U.K., Germany, France, Spain, Italy, Russia, Benelux, Rest of Europe) APAC(China, South Korea, Japan, India, Australia, ASEAN, Rest of Asia-Pacific) Middle East & Africa(GCC, Turkey, South Africa, Rest of MEA) LATAM(Brazil, Argentina, Chile, Rest of LATAM) |
Top Key Players & Competitive Landscape :
The competitive landscape encompasses major innovators, aftermarket service providers, industry giants, and niche players, all of which are thoroughly examined by Consegic Business Intelligence in terms of their strengths, weaknesses, and value-addition potential. This report includes detailed profiles of key players, market share analysis, mergers and acquisitions, resulting market fragmentation, and emerging partnership trends and dynamics.
List of prominent players in the ACE Inhibitors Industry:
- Pfizer Inc. (USA)
- Novartis International AG (Switzerland)
- Merck & Co., Inc. (USA)
- Sanofi S.A. (France)
- Johnson & Johnson (USA)
- AstraZeneca (UK)
- Bristol-Myers Squibb Company (USA)
- Abbott Laboratories (USA)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Mylan N.V. (USA)
Recent Industry Developments :
- In July 2022, Solco Healthcare, in collaboration with Zhejiang Huahai Pharmaceutical, received FDA approval for Enalapril Maleate tablets, a generic equivalent of Vasotec by Bausch Health.
- In February 2022, Camber Pharmaceuticals launched Enalapril Maleate Oral Solution, designed to manage blood pressure in adults and children over one month old.
